# A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

> **NCT04056468** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** Mobocertinib

## Key facts

- **NCT ID:** NCT04056468
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-09
- **Primary completion:** 2022-02-05
- **Final completion:** 2022-02-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056468, "A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04056468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*